Get started
Work

Chronic graft-vs-host disease in 2016: a major challenge and an opportunity

Year: 2016
Type: article
Abstract: Despite major advances in the treatment of hematological diseases over the last decades, allogeneic hematopoietic stem cell transplantation (alloHSCT) still remains the only curative option for many of them.According to the recent survey of the European Society of Blood and Marrow Transplantation (EBMT), nearly 15 000 alloHSCT are currently performed each year across Europe and EBMTaffiliated countries (1).
DOI: 10.3325/cmj.2016.57.1
Authors: Dražen Pulanić, Lana Desnica, Radovan Vrhovac, Damir Nemet, Daniel Wolff, Hildegard Greinix, Steven Z. Pavletic
Institutions: University Hospital Centre Zagreb, University of Zagreb, University of Osijek, University Hospital Regensburg, University of Regensburg, Medical University of Graz, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W2420306194
FWCI: 0.263
Cites: 19
Cited by: 5
Related to: 10